| Active, not recruiting | 2/3 | 110 | Europe, US | AMX0035, Placebo | Amylyx Pharmaceuticals Inc. | Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism | 04/26 | 11/29 | | |
| Active, not recruiting | N/A | 315 | Canada, US | AIDP | University of Florida, Augusta University, Albany Medical College, Beth Israel Deaconess Medical Center, Duke University, Johns Hopkins University, Massachusetts General Hospital, Northwestern University, Ottawa Hospital Research Institute, Penn State University, University of Alabama at Birmingham, University of California, San Diego, University of California, San Francisco, University of Chicago, University of Michigan, University of Minnesota, University of South Florida, Centre for Addiction and Mental Health, Wake Forest University, Washington University School of Medicine, University of Kentucky, National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy | 03/26 | 03/26 | | |
